Presence of sst5TMD4, a truncated splice variant of the somatostatin receptor subtype 5, is associated to features of increased aggressiveness in pancreatic neuroendocrine tumors
Oncotarget2015Vol. 7(6), pp. 6593–6608
Citations Over TimeTop 10% of 2015 papers
Miguel Sampedro‐Núñez, Raúl M. Luque, Ana M. Ramos‐Leví, Manuel D. Gahete, Ana Serrano-Somavilla, Alicia Villa-Osaba, Magdalena Adrados, Alejandro Ibáñez‐Costa, Elena Martín‐Pérez, Michael D. Culler, Mónica Marazuela, Justo P. Castaño
Abstract
sst5TMD4 is overexpressed in GEP-NETs and is associated to enhanced aggressiveness, suggesting its potential value as biomarker and target in GEP-NETs.
Related Papers
- → Pasireotide, a multi-somatostatin receptor ligand with potentialefficacy for treatment of pituitary and neuroendocrine tumors(2013)24 cited
- → Pituitary Somatostatin Receptor (sst)1–5 Expression during Rat Development: Age-Dependent Expression of sst21(1999)39 cited
- → Octreotide inhibits insulin-like growth factor-I hepatic gene expression in the hypophysectomized rat: evidence for a direct and indirect mechanism of action.(1992)55 cited
- → The Somatostatin Analog Octreotide Inhibits the Secretion of Growth Hormone (GH)-Releasing Hormone, Thyrotropin, and GH in Man*(1989)20 cited
- → The Somatostatin Analog Octreotide Inhibits GH-Stimulated, But Not IGF-I-Stimulated, Bone Growth in Hypophysectomized Rats(2002)16 cited